Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Krystal Biotech (KRYS) Total Non-Current Liabilities (2024 - 2025)

Historic Total Non-Current Liabilities for Krystal Biotech (KRYS) over the last 3 years, with Q3 2025 value amounting to $99.1 million.

  • Krystal Biotech's Total Non-Current Liabilities rose 352.1% to $99.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $99.1 million, marking a year-over-year increase of 352.1%. This contributed to the annual value of $108.0 million for FY2024, which is 17204.26% up from last year.
  • Latest data reveals that Krystal Biotech reported Total Non-Current Liabilities of $99.1 million as of Q3 2025, which was up 352.1% from $94.9 million recorded in Q2 2025.
  • In the past 5 years, Krystal Biotech's Total Non-Current Liabilities ranged from a high of $108.0 million in Q4 2024 and a low of $39.7 million during Q4 2023
  • In the last 3 years, Krystal Biotech's Total Non-Current Liabilities had a median value of $94.9 million in 2025 and averaged $86.2 million.
  • Per our database at Business Quant, Krystal Biotech's Total Non-Current Liabilities soared by 17204.26% in 2024 and then skyrocketed by 352.1% in 2025.
  • Krystal Biotech's Total Non-Current Liabilities (Quarter) stood at $39.7 million in 2023, then surged by 172.04% to $108.0 million in 2024, then decreased by 8.29% to $99.1 million in 2025.
  • Its last three reported values are $99.1 million in Q3 2025, $94.9 million for Q2 2025, and $87.7 million during Q1 2025.